{"protocolSection":{"identificationModule":{"nctId":"NCT02754882","orgStudyIdInfo":{"id":"SB8-G31-NSCLC"},"organization":{"fullName":"Samsung Bioepis Co., Ltd.","class":"INDUSTRY"},"briefTitle":"A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer","officialTitle":"A Phase 3, Randomised, Double-blind Study to Compare the Efficacy, Safety, PK and Immunogenicity Between SB8 (Proposed Bevacizumab Biosimilar) and Avastin® in Subjects With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-07-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-01-24","type":"ACTUAL"},"completionDateStruct":{"date":"2018-10-09","type":"ACTUAL"},"studyFirstSubmitDate":"2016-03-24","studyFirstSubmitQcDate":"2016-04-25","studyFirstPostDateStruct":{"date":"2016-04-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-07-01","resultsFirstSubmitQcDate":"2024-12-11","resultsFirstPostDateStruct":{"date":"2024-12-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-12-11","lastUpdatePostDateStruct":{"date":"2024-12-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Samsung Bioepis Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study is designed to establish biosimilarity of SB8, a proposed biosimilar product of bevacizumab, to EU-sourced bevacizumab, in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).","detailedDescription":"Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be compared between SB8 and bevacizumab."},"conditionsModule":{"conditions":["Lung Cancer","Non-small Cell Lung Cancer"],"keywords":["NSCLC","bevacizumab","avastin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":763,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bevacizumab (Avastin)","type":"ACTIVE_COMPARATOR","description":"Avastin® + Carboplatin/Paclitaxel","interventionNames":["Drug: Bevacizumab","Drug: Carboplatin","Drug: Paclitaxel"]},{"label":"SB8 (A proposed bevacizumab biosimilar)","type":"EXPERIMENTAL","description":"SB8 + Carboplatin/Paclitaxel","interventionNames":["Drug: SB8","Drug: Carboplatin","Drug: Paclitaxel"]}],"interventions":[{"type":"DRUG","name":"Bevacizumab","description":"Avastin® 15 mg/kg IV every 3 weeks on Day 1","armGroupLabels":["Bevacizumab (Avastin)"],"otherNames":["Avastin®"]},{"type":"DRUG","name":"SB8","description":"SB8 15 mg/kg IV every 3 weeks on Day 1","armGroupLabels":["SB8 (A proposed bevacizumab biosimilar)"],"otherNames":["SB8 (A proposed bevacizumab biosimilar)"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles","armGroupLabels":["Bevacizumab (Avastin)","SB8 (A proposed bevacizumab biosimilar)"]},{"type":"DRUG","name":"Paclitaxel","description":"Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles","armGroupLabels":["Bevacizumab (Avastin)","SB8 (A proposed bevacizumab biosimilar)"],"otherNames":["Taxol"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks","description":"The best ORR was defined as the proportion of subjects whose best overall response was either Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 during the induction treatment period by 24 weeks.\n\nCR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"24 weeks from randomisation"}],"secondaryOutcomes":[{"measure":"Progression Free Survival","description":"PFS is defined as the time from the date of Randomisation to the date of disease progression (progressive disease \\[PD\\]) or death regardless of the cause of death.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","timeFrame":"from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject"},{"measure":"Overall Survival","description":"OS was defined as the time from the date of randomisation to the date of death regardless of the cause of death.\n\nSubjects who were alive at the time of analysis were censored at the date of last known alive.","timeFrame":"from the date of randomisation to the date of death up to 12 months from randomisation of the last subject"},{"measure":"Duration of Response (DoR)","description":"DoR in subjects with response from documented tumour response until disease progression up to 12 months from randomisation of the last subject","timeFrame":"from documented tumour response until disease progression up to 12 months from randomisation of the last subject"},{"measure":"Number of Participants With Treatment-related Adverse Events Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03","description":"After the end of treatment (EOT) visit, SAEs should be reported to the Sponsor if the Investigator becomes aware of them.\n\nSeverity Grade of NCI-CTCAE v4.03 Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) (Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalisation or prolongation of hospitalisation indicated; disabling; limiting self-care ADL (Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.) Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death related to AE","timeFrame":"AEs were reported from the time the informed consent form (ICF) was signed until the EOT visit, approximately 24 months from study initiation."},{"measure":"Pharmacokinetics: Trough Level [Ctrough]","description":"Ctrough at selected cycles (i.e., Cycle 1, 3, 5 and 7)","timeFrame":"Up to 21 weeks (Cycle 1,3,5 and 7. Each cycle is 21 days.)"},{"measure":"Pharmacokinetics: Maximum Plasma Concentration [Cmax]","description":"Maximum Plasma Concentration (Cmax) at selected cycles (i.e., Cycle 1, 3, 5 and 7)","timeFrame":"Up to 21 weeks (Cycle 1,3,5 and 7. Each cycle is 21 days.)"},{"measure":"Immunogenicity Assessments (Anti-drug Antibodies)","description":"Incidence of anti-drug (bevacizumab) antibodies (ADA)\n\nThe incidence of overall ADA results (i.e. Positive, Negative, Inconclusive) was presented by treatment group at Cycle 7 and the end of treatment (EOT). Overall ADA result was defined as below:\n\n* 'Positive' for a subject with treatment-induced or treatment-boosted ADA, where treatment-induced ADA indicated at least one positive result after pre-dose of Cycle 1 for subjects with negative ADA at pre-dose of Cycle 1, and treatment-boosted ADA indicated at least one positive result with higher titre level compared to pre-dose of Cycle 1 after pre-dose of Cycle 1 for subjects with positive ADA at pre-dose of Cycle 1.\n* 'Negative' for a subject without positive ADA until Cycle 7 and EOT.\n* 'Inconclusive' for a subject with positive ADA at Cycle 1 and without positive result with higher titre level observed after pre-dose of Cycle 1 up to Cycle 7 and EOT.","timeFrame":"Up to 21 weeks (Cycle 1,3,5, 7 and EOT visit. Each cycle is 21 days.), approximately 24 months from study initiation."},{"measure":"Immunogenicity Assessments (Neutralizing Antibodies)","description":"Incidence of anti-drug (bevacizumab) antibodies (ADA) - neutralizing antibodies (NAb) The analysis was performed using the Safety Set (SAF). Overall Number of Participants Analyzed represents the number of subjects in SAF.\n\nThe total number is not the sum of the number of subjects of each visits, since NAb results only for subjects with ADA positive against SB8 or Avastin were used for the summary.\n\nNumber Analyzed of each visit is equal to the number of subjects with ADA positive of each visit, which is displayed in 8. Secondary Outcome: Immunogenicity Assessments (Anti-drug Antibodies).","timeFrame":"Up to 21 weeks (Cycle 1,3,5, 7 and EOT visit. Each cycle is 21 days.), approximately 24 months from study initiation."}],"otherOutcomes":[{"measure":"Best Objective Response Rate by 11 and 17 Weeks","description":"Best Objective Response Rate (ORR) by 11 weeks and 17 weeks","timeFrame":"11 weeks and 17 weeks from randomisation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged ≥ 18 years\n2. ECOG performance status of 0-1\n3. Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung cancer\n4. At least one measurable lesion according to RECIST v1.1.\n5. Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory and clinical parameters\n\nExclusion Criteria:\n\n1. Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma\n2. Sensitizing EGFR mutations or ALK rearrangements\n3. Increased risk of bleeding determined by investigator based on radiographic / clinical findings\n4. History of systemic chemotherapy administered in the first-line setting for metastatic or recurrent disease of NSCLC.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Martin Reck, M.D.","affiliation":"LungenClinic Grosshansdorf, Germany","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Brest Regional Oncology Dispensary","city":"Brest","zip":"224027","country":"Belarus","geoPoint":{"lat":52.10894,"lon":23.71749}},{"facility":"Grodno Regional Clinical Hospital","city":"Grodno","zip":"230017","country":"Belarus","geoPoint":{"lat":53.62865,"lon":23.8942}},{"facility":"N. N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology","city":"Lesnoy","zip":"223040","country":"Belarus","geoPoint":{"lat":51.8625,"lon":26.7547}},{"facility":"Minsk city Clinical Oncological Dispensary","city":"Minsk","zip":"220013","country":"Belarus","geoPoint":{"lat":53.90019,"lon":27.56653}},{"facility":"Mogilev Regional Oncological Dispensary","city":"Mogilev","zip":"212018","country":"Belarus","geoPoint":{"lat":53.90876,"lon":30.34044}},{"facility":"Vitebsk Regional Clinical Oncological Dispensary","city":"Vitebsk","zip":"210603","country":"Belarus","geoPoint":{"lat":55.1904,"lon":30.2049}},{"facility":"JSC Maritime Hospital","city":"Batumi","zip":"6010","country":"Georgia","geoPoint":{"lat":41.64077,"lon":41.6306}},{"facility":"JSC Saint Nikolozi Surgery Center","city":"Kutaisi","zip":"4600","country":"Georgia","geoPoint":{"lat":42.26791,"lon":42.69459}},{"facility":"LTD Research Institute of Clinical Medicine","city":"Tbilisi","zip":"0112","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"ICO-Institute of Clinical Oncology","city":"Tbilisi","zip":"0159","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"New Vision University Hospital","city":"Tbilisi","zip":"0159","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"LTD MediClubGeorgia","city":"Tbilisi","zip":"0160","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Institute for Personalized Medicine LTD","city":"Tbilisi","zip":"0186","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"LTD Chemotherapy and Immunotherapy Clinic Medulla","city":"Tbilisi","zip":"0186","country":"Georgia","geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Evangelisches Krankenhaus Bielefeld","city":"Bielefeld","zip":"33611","country":"Germany","geoPoint":{"lat":52.03333,"lon":8.53333}},{"facility":"Universitätsklinikum Bonn","city":"Bonn","zip":"53127","country":"Germany","geoPoint":{"lat":50.73438,"lon":7.09549}},{"facility":"LungenClinic Grosshansdorf GmbH","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"University Hospital Homburg","city":"Homburg","zip":"66421","country":"Germany","geoPoint":{"lat":49.32637,"lon":7.33867}},{"facility":"Klinikum Kassel","city":"Kassel","zip":"34125","country":"Germany","geoPoint":{"lat":51.31667,"lon":9.5}},{"facility":"Universitätsklinikum Leipzig [Pneumologie]","city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Klinik Löwenstein","city":"Löwenstein","zip":"74245","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"Klinikum der Stadt Ludwigshafen","city":"Ludwigshafen","zip":"67063","country":"Germany","geoPoint":{"lat":47.81663,"lon":9.06138}},{"facility":"Országos Korányi TBC és Pulmonológiai Intézet","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Országos Korányi TBC és Pulmonológiai Intézet","city":"Budapest","zip":"1521","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Orszagos Koranyi Tbc Es Pulmonologiai Intezet, Iv. Tudobel","city":"Budapest","zip":"H-1529","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkó","city":"Deszk","zip":"6772","country":"Hungary","geoPoint":{"lat":46.21802,"lon":20.24322}},{"facility":"Veszprem Megyei Onkormanyzat Tudogyogyintezete","city":"Farkasgyepű","zip":"8582","country":"Hungary","geoPoint":{"lat":47.2,"lon":17.63333}},{"facility":"Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendeloint","city":"Szolnok","zip":"5004","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Markusovszky Egyetemi Oktatókórház","city":"Szombathely","zip":"H-9700","country":"Hungary","geoPoint":{"lat":47.23088,"lon":16.62155}},{"facility":"Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"MED-POLONIA Sp.z o.o.","city":"Poznan","zip":"60-693","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Med Life","city":"Bucharest","zip":"031784","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Spitalul Universitar de Urgenta Bucuresti","city":"Bucharest","zip":"050098","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Medisprof","city":"Cluj-Napoca","zip":"400058","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Spitalul Clinic Judetean de Urgenta Constanta","city":"Constanța","zip":"900591","country":"Romania","geoPoint":{"lat":44.18073,"lon":28.63432}},{"facility":"Centrul de Oncologie Sf. Nectarie","city":"Craiova","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Oncolab","city":"Craiova","zip":"200385","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Radiotherapy Center CJ radioterapie si chimioterapie adulti","city":"Floreşti","zip":"407280","country":"Romania","geoPoint":{"lat":45.05,"lon":25.78333}},{"facility":"Centrul de Oncologie Euroclinic","city":"Iași","zip":"700106","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"Institutul Regional de Oncologie Iasi","city":"Iași","zip":"700483","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"Pelican Impex","city":"Oradea","zip":"410469","country":"Romania","geoPoint":{"lat":47.0458,"lon":21.91833}},{"facility":"Oncocenter Oncologie Clinica","city":"Timișoara","zip":"300210","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"State Budgetary Institution of Arkhangelsk Oblast \"Arkhangelsk Region Clinical Oncology Center","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"State Budgetary Healthcare Institution \"Chelyabinsk Regional Clinical Oncology Center\"","city":"Chelyabinsk","zip":"454087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"State Autonomous Healthcare Institution \"Republican Clinical Oncology Center of Ministry of Healthcare of Tatarstan Republic\"","city":"Kazan'","zip":"420029","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"State Budgetary Healthcare Institution \"Regional Clinical Hospital #1 n.a. professor S.V. Ochapovsky\" of Ministry of Healthcare of Krasnodar Region","city":"Krasnodar","zip":"350086","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"facility":"Federal State Budgetary Scientific Institution \" N.N. Blokhin Russian Cancer Research Center\" of the Ministry of Health of the Russian Federation","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"State Autonomous Healthcare Institution of Moscow \"Moscow City Oncology Hospital # 62 of Healthcare Department of Moscow\"","city":"Moscow","zip":"143423","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"State Regional Budgetary Healthcare Institution \"Murmansk Regional Oncology Center\"","city":"Murmansk","zip":"183047","country":"Russia","geoPoint":{"lat":68.96778,"lon":33.09922}},{"facility":"State Budgetary Healthcare Institution of Nizhny Novgorod oblast \"Nizhny Novgorod Region Oncology Center\"","city":"Nizhny Novgorod","zip":"603081","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"State Budgetary Healthcare Institution of Novosibirsk Region \"Novosibirsk Region Clinical Oncology Center\"","city":"Novosibirsk","zip":"630108","country":"Russia","geoPoint":{"lat":55.02259,"lon":82.93175}},{"facility":"Budgetary Healthcare Institution of Omsk Region \"Clinical Oncology Center\"","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"Federal Budgetary Healthcare Insittution \"Saint-Petersburg Clinical Hospital of RAS\"","city":"Saint Petersburg","zip":"194017","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"State Budgetary Healthcare Institution Leningradskaya Region Clinical Hospital","city":"Saint Petersburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Federal State Budgetary Educational Institution of Higher Education \"Academician I.P. Pavlov First St. Petersburg State Medical University\" of the Ministry of Healthcare of the Russian Federation./ Scientific Research Institute of Pulmonology","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Federal State Budgetary Institution \" Scientific Research Institute of Oncology n.a. N.N. Petrov\" of Ministry of Healthcare of the Russian Federation","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Saint-Petersburg State Budgetary Healthcare Institution \"City Clinical Oncology Center\"","city":"Saint Petersburg","zip":"198255","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Private foundation of Educational establishment of Higher Education Medical University \"REAVIZ\"","city":"Samara","zip":"443011","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"State Budgetary Healthcare Institution \" Oncology Center #2\" of Krasnodar Region Ministry of Healthcare","city":"Sochi","zip":"354057","country":"Russia","geoPoint":{"lat":43.59699,"lon":39.72477}},{"facility":"State Budgetary Healthcare Institution Republican Clinical Oncology Center of Ministry of Healthcare of the Republic of Bashkortostan","city":"Ufa","zip":"450054","country":"Russia","geoPoint":{"lat":54.74306,"lon":55.96779}},{"facility":"State Budgetary Healthcare Institution \"Volgograd Regional Clinical Oncology Center\"","city":"Volzhskiy","zip":"404130","country":"Russia","geoPoint":{"lat":53.43058,"lon":50.119}},{"facility":"State Budgetary Healthcare Institution of Yaroslavl Region \"Regional Clinical Oncology Hospital\"","city":"Yaroslavl","zip":"150040","country":"Russia","geoPoint":{"lat":57.62987,"lon":39.87368}},{"facility":"State Budgetary Healthcare Institution of Sverdlovskaya Oblast \"Sverdlovsk Regional Oncology Center\"","city":"Yekaterinburg","zip":"620036","country":"Russia","geoPoint":{"lat":56.85733,"lon":60.61529}},{"facility":"Military Medical Academy","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Clinical Hospital Center Bezanijska Kosa","city":"Belgrade","zip":"11070","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Clinical Center Kragujevac, Clinic for Pulmology","city":"Kragujevac","zip":"34000","country":"Serbia","geoPoint":{"lat":44.01667,"lon":20.91667}},{"facility":"Clinical Centre Nis","city":"Niš","zip":"18000","country":"Serbia","geoPoint":{"lat":43.32472,"lon":21.90333}},{"facility":"Inje University Haeundae Paik Hospital","city":"Busan","zip":"48108","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Dong-A University Hospital","city":"Busan","zip":"49201","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Chonbuk National University Hospital","city":"Jeonju","zip":"561-712","country":"South Korea","geoPoint":{"lat":35.82194,"lon":127.14889}},{"facility":"Gyeongsang National University Hospital","city":"Jinju","zip":"52727","country":"South Korea","geoPoint":{"lat":35.19278,"lon":128.08472}},{"facility":"CHA Bundang Medical Center, CHA University","city":"Seongnam","zip":"13496","country":"South Korea","geoPoint":{"lat":35.54127,"lon":127.39683}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam","zip":"13620","country":"South Korea","geoPoint":{"lat":35.54127,"lon":127.39683}},{"facility":"Gangnam Severance Hospital, Yonsei University Health System","city":"Seoul","zip":"06273","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Catholic University of Korea, St. Vincent's Hospital","city":"Suwon","zip":"442-723","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Yonsei Universtiy, Wonju Severance Christian Hospital","city":"Wŏnju","zip":"26426","country":"South Korea","geoPoint":{"lat":37.35139,"lon":127.94528}},{"facility":"C.H. Provincial de Castellón","city":"Castellon","zip":"12002","country":"Spain","geoPoint":{"lat":39.98567,"lon":-0.04935}},{"facility":"H.U. Severo Ochoa","city":"Leganés","zip":"28911","country":"Spain","geoPoint":{"lat":40.32718,"lon":-3.7635}},{"facility":"H.G.U. G. Marañón","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"H.U. F. Jiménez Díaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"C.H. de Orense","city":"Ourense","zip":"32005","country":"Spain","geoPoint":{"lat":42.33669,"lon":-7.86407}},{"facility":"Clínica Universidad de Navarra","city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"H.U. Sant Joan de Reus","city":"Reus","zip":"43204","country":"Spain","geoPoint":{"lat":41.15612,"lon":1.10687}},{"facility":"C.H.U. de Canarias","city":"Santa Cruz de Tenerife","zip":"38320","country":"Spain","geoPoint":{"lat":28.46824,"lon":-16.25462}},{"facility":"H.U.N. Sra. Valme","city":"Seville","zip":"41014","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Changhua Christian Hospital","city":"Changhua","zip":"50006","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"Kaohsiung Medical University Chung-Ho Memorial Hospital","city":"Kaohsiung City","zip":"807","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"E-Da Hospital","city":"Kaohsiung City","zip":"824","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"China Medical University Hospital","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Chang Gung Medical Foundation, Linkou","city":"Taoyuan District","zip":"33305","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}},{"facility":"Siriraj Hospital","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"ChiangMai Univerisity","city":"Chiang Mai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"Chiangrai Prachanukroh Hospital","city":"Chiang Rai","zip":"57000","country":"Thailand","geoPoint":{"lat":19.90858,"lon":99.8325}},{"facility":"Prince of Songkla University","city":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Udonthani Cancer Hospital","city":"Udon Thani","zip":"41330","country":"Thailand","geoPoint":{"lat":17.41567,"lon":102.78589}},{"facility":"Komunalna ustanova \"Chernivetskyi oblasnyi klinichnyi onkolo","city":"Chernivtsi","zip":"58013","country":"Ukraine","geoPoint":{"lat":48.29045,"lon":25.93241}},{"facility":"Komunalnyi zaklad Miska bahatoprofilna klinichna likarnia #4","city":"Dnipropetrovsk","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr","city":"Kharkiv","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Khmelnytskyi oblasnyi onkolohichnyi dyspanser","city":"Khmelnytskyi","zip":"29009","country":"Ukraine","geoPoint":{"lat":49.41835,"lon":26.97936}},{"facility":"Odeskyi oblasnyi onkolohichnyi dyspanser","city":"Odesa","zip":"65055","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"OKZ \"Sumskyi oblasnyi klinichnyi onkolohichnyi dyspanser\"","city":"Sumy","zip":"40022","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Vinnytskyi oblasnyi klinichnyi onkolohichnyi dyspanser","city":"Vinnytsia","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Zaporozhye Regional Clinical Oncology Center","city":"Zaporizhzhya","zip":"69040","country":"Ukraine","geoPoint":{"lat":47.85167,"lon":35.11714}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"FG001","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"384"},{"groupId":"FG001","numSubjects":"379"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"35"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"346"},{"groupId":"FG001","numSubjects":"344"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"BG001","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"384"},{"groupId":"BG001","value":"379"},{"groupId":"BG002","value":"763"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"255"},{"groupId":"BG002","value":"524"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"239"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.0","spread":"9.18"},{"groupId":"BG001","value":"60.2","spread":"8.95"},{"groupId":"BG002","value":"60.1","spread":"20.84"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"127"},{"groupId":"BG002","value":"255"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"256"},{"groupId":"BG001","value":"252"},{"groupId":"BG002","value":"508"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"67"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"348"},{"groupId":"BG001","value":"347"},{"groupId":"BG002","value":"695"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25.49","spread":"4.707"},{"groupId":"BG001","value":"25.50","spread":"4.809"},{"groupId":"BG002","value":"25.50","spread":"4.755"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks","description":"The best ORR was defined as the proportion of subjects whose best overall response was either Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 during the induction treatment period by 24 weeks.\n\nCR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","populationDescription":"The Full Analysis Set consisted of all randomised subjects. The subjects were analysed based on the treatment they were randomised to by intention-to-treat principle. However, subjects who did not qualify for randomisation and were inadvertently randomised into the study were excluded from FAS, provided these subjects did not receive any IP, and there was one subject who met these criteria. So, there is a difference between \"Started\" in Participant Flow module and Analysis Population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"24 weeks from randomisation","groups":[{"id":"OG000","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"379"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8"},{"groupId":"OG001","value":"47.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Pre-defined equivalence margin was \\[0.737, 1.357\\]","paramType":"Risk Ratio (RR)","paramValue":"1.11","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.975","ciUpperLimit":"1.269","estimateComment":"SB8 vs. Avastin"}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"PFS is defined as the time from the date of Randomisation to the date of disease progression (progressive disease \\[PD\\]) or death regardless of the cause of death.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","populationDescription":"Full Analysis Set (FAS): Consisted of all randomised subjects. The subjects were analysed based on the treatment they were randomised to by intention-to-treat principle. Per-protocol Set (PPS): Consisted of all FAS subjects who completed at least first 2 cycles of combination chemotherapy with a tumour assessment and did not have any major protocol deviations that impacted the primary efficacy assessment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"classes":[{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.50","lowerLimit":"7.40","upperLimit":"9.70"},{"groupId":"OG001","value":"7.90","lowerLimit":"7.40","upperLimit":"9.50"}]}]},{"title":"PPS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.50","lowerLimit":"7.20","upperLimit":"9.70"},{"groupId":"OG001","value":"7.90","lowerLimit":"7.30","upperLimit":"9.40"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"OS was defined as the time from the date of randomisation to the date of death regardless of the cause of death.\n\nSubjects who were alive at the time of analysis were censored at the date of last known alive.","populationDescription":"Full Analysis Set (FAS): Consisted of all randomised subjects. The subjects were analysed based on the treatment they were randomised to by intention-to-treat principle.\n\nPer-protocol Set (PPS): Consisted of all FAS subjects who completed at least first 2 cycles of combination chemotherapy with a tumour assessment and did not have any major protocol deviations that impacted the primary efficacy assessment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"from the date of randomisation to the date of death up to 12 months from randomisation of the last subject","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"classes":[{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.90","lowerLimit":"13.30","upperLimit":"17.10"},{"groupId":"OG001","value":"15.80","lowerLimit":"13.60","upperLimit":"17.10"}]}]},{"title":"PPS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.80","lowerLimit":"13.00","upperLimit":"17.10"},{"groupId":"OG001","value":"15.80","lowerLimit":"13.80","upperLimit":"17.70"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR in subjects with response from documented tumour response until disease progression up to 12 months from randomisation of the last subject","populationDescription":"Full Analysis Set (FAS): Consisted of all randomised subjects. The subjects were analysed based on the treatment they were randomised to by intention-to-treat principle.\n\nPer-protocol Set (PPS): Consisted of all FAS subjects who completed at least first 2 cycles of combination chemotherapy with a tumour assessment and did not have any major protocol deviations that impacted the primary efficacy assessment.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"months","timeFrame":"from documented tumour response until disease progression up to 12 months from randomisation of the last subject","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"classes":[{"title":"FAS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.38","spread":"3.773"},{"groupId":"OG001","value":"6.79","spread":"4.117"}]}]},{"title":"PPS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.33","spread":"3.784"},{"groupId":"OG001","value":"6.81","spread":"4.177"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-related Adverse Events Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03","description":"After the end of treatment (EOT) visit, SAEs should be reported to the Sponsor if the Investigator becomes aware of them.\n\nSeverity Grade of NCI-CTCAE v4.03 Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) (Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalisation or prolongation of hospitalisation indicated; disabling; limiting self-care ADL (Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.) Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death related to AE","populationDescription":"Safety Set (SAF): The Safety Set consisted of all subjects who received the study drug at least once.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"AEs were reported from the time the informed consent form (ICF) was signed until the EOT visit, approximately 24 months from study initiation.","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"380"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"346"}]}]},{"title":"CTCAE Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"57"}]}]},{"title":"CTCAE Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"134"}]}]},{"title":"CTCAE Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"97"}]}]},{"title":"CTCAE Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"31"}]}]},{"title":"CTCAE Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"27"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Trough Level [Ctrough]","description":"Ctrough at selected cycles (i.e., Cycle 1, 3, 5 and 7)","populationDescription":"Pharmacokinetic Population (PK Population): This set consisted of subjects allocated to PK sub-study who had at least one measured serum concentration of bevacizumab.\n\nPK analyses were performed on the PK population. The number of participants analyzed in each Cycle is the number of participants in PK population with non-missing values or without protocol deviation for PK blood sampling at the cycle.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ug/mL","timeFrame":"Up to 21 weeks (Cycle 1,3,5 and 7. Each cycle is 21 days.)","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"180"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.00000"},{"groupId":"OG001","value":"0.0000","spread":"0.00000"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"152"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.7568","spread":"44.49701"},{"groupId":"OG001","value":"102.3939","spread":"69.36822"}]}]},{"title":"Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"109.0906","spread":"50.65915"},{"groupId":"OG001","value":"119.9343","spread":"54.65786"}]}]},{"title":"Cycle 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"121.7382","spread":"62.62150"},{"groupId":"OG001","value":"133.7669","spread":"58.84136"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Maximum Plasma Concentration [Cmax]","description":"Maximum Plasma Concentration (Cmax) at selected cycles (i.e., Cycle 1, 3, 5 and 7)","populationDescription":"Pharmacokinetic Population (PK Population): This set consisted of subjects allocated to PK sub-study who had at least one measured serum concentration of bevacizumab.\n\nPK analyses were performed on the PK population. The number of participants analyzed in each Cycle is the number of participants in PK population with non-missing values or without protocol deviation for PK blood sampling at the cycle.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ug/mL","timeFrame":"Up to 21 weeks (Cycle 1,3,5 and 7. Each cycle is 21 days.)","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"180"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"170"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"306.0352","spread":"98.71872"},{"groupId":"OG001","value":"302.6362","spread":"87.10467"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"374.9657","spread":"106.54366"},{"groupId":"OG001","value":"399.4598","spread":"136.27431"}]}]},{"title":"Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"389.3132","spread":"123.07791"},{"groupId":"OG001","value":"397.6183","spread":"125.84175"}]}]},{"title":"Cycle 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"397.5435","spread":"120.74092"},{"groupId":"OG001","value":"426.1350","spread":"144.24538"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Assessments (Anti-drug Antibodies)","description":"Incidence of anti-drug (bevacizumab) antibodies (ADA)\n\nThe incidence of overall ADA results (i.e. Positive, Negative, Inconclusive) was presented by treatment group at Cycle 7 and the end of treatment (EOT). Overall ADA result was defined as below:\n\n* 'Positive' for a subject with treatment-induced or treatment-boosted ADA, where treatment-induced ADA indicated at least one positive result after pre-dose of Cycle 1 for subjects with negative ADA at pre-dose of Cycle 1, and treatment-boosted ADA indicated at least one positive result with higher titre level compared to pre-dose of Cycle 1 after pre-dose of Cycle 1 for subjects with positive ADA at pre-dose of Cycle 1.\n* 'Negative' for a subject without positive ADA until Cycle 7 and EOT.\n* 'Inconclusive' for a subject with positive ADA at Cycle 1 and without positive result with higher titre level observed after pre-dose of Cycle 1 up to Cycle 7 and EOT.","populationDescription":"The analysis was performed using the Safety Set (SAF). The SAF consisted of all subjects who received the study drug at least once. This analysis set was used for the safety analyses. The subjects were analysed based on the treatment they received.\n\nThere were 4 subjects in Avastin group and 1 subject in SB8 group who had not received any IP or non-IP treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 21 weeks (Cycle 1,3,5, 7 and EOT visit. Each cycle is 21 days.), approximately 24 months from study initiation.","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"380"}]}],"classes":[{"title":"Cycle 1 (BL)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"372"},{"groupId":"OG001","value":"371"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"356"}]},{"title":"Inconclusive (only applicable for \"Overall\")","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"338"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"22"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"316"}]},{"title":"Inconclusive (only applicable for \"Overall\")","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"296"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"21"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"275"}]},{"title":"Inconclusive (only applicable for \"Overall\")","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cycle 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"279"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"20"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"259"}]},{"title":"Inconclusive (only applicable for \"Overall\")","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"EOT","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"161"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"9"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"152"}]},{"title":"Inconclusive (only applicable for \"Overall\")","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cycle 7 Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"337"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"34"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"294"}]},{"title":"Inconclusive (only applicable for \"Overall\")","measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"}]}]},{"title":"EOT Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"337"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"37"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"291"}]},{"title":"Inconclusive (only applicable for \"Overall\")","measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Assessments (Neutralizing Antibodies)","description":"Incidence of anti-drug (bevacizumab) antibodies (ADA) - neutralizing antibodies (NAb) The analysis was performed using the Safety Set (SAF). Overall Number of Participants Analyzed represents the number of subjects in SAF.\n\nThe total number is not the sum of the number of subjects of each visits, since NAb results only for subjects with ADA positive against SB8 or Avastin were used for the summary.\n\nNumber Analyzed of each visit is equal to the number of subjects with ADA positive of each visit, which is displayed in 8. Secondary Outcome: Immunogenicity Assessments (Anti-drug Antibodies).","populationDescription":"The analysis was performed using the Safety Set (SAF). The SAF consisted of all subjects who received the study drug at least once. This analysis set was used for the safety analyses. The subjects were analysed based on the treatment they received.\n\nThere were 4 subjects in Avastin group and 1 subject in SB8 group who had not received any IP or non-IP treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 21 weeks (Cycle 1,3,5, 7 and EOT visit. Each cycle is 21 days.), approximately 24 months from study initiation.","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"380"}]}],"classes":[{"title":"Cycle 1 (BL)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"22"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}]}]},{"title":"Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"21"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"}]}]},{"title":"Cycle 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"20"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"}]}]},{"title":"EOT","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"9"}]}],"categories":[{"title":"Positive","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]},{"title":"Negative","measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Best Objective Response Rate by 11 and 17 Weeks","description":"Best Objective Response Rate (ORR) by 11 weeks and 17 weeks","populationDescription":"Full Analysis Set (FAS): Consisted of all randomised subjects. The subjects were analysed based on the treatment they were randomised to by intention-to-treat principle.\n\nPer-protocol Set (PPS): Consisted of all FAS subjects who completed at least first 2 cycles of combination chemotherapy with a tumour assessment and did not have any major protocol deviations that impacted the primary efficacy assessment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"11 weeks and 17 weeks from randomisation","groups":[{"id":"OG000","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"},{"id":"OG001","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"classes":[{"title":"11 Weeks (FAS)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"100"}]}]},{"title":"11 Weeks (PPS)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"89"}]}]},{"title":"17 Weeks (FAS)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"383"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"152"}]}]},{"title":"17 Weeks (PPS)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"328"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"137"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"AEs were reported from the time the ICF was signed until the EOT visit, approximately 24 months from study initiation.","description":"All safety analyses were performed using the Safety Set (SAF). The SAF consisted of all subjects who received the study drug at least once. This analysis set was used for the safety analyses. The subjects were analysed based on the treatment they received.\n\nThere were 4 subjects in Avastin group and 1 subject in SB8 group who had not received any IP or non-IP treatment.","eventGroups":[{"id":"EG000","title":"Bevacizumab (Avastin)","description":"Avastin® + Carboplatin/Paclitaxel\n\nBevacizumab: Avastin® 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles","deathsNumAffected":171,"deathsNumAtRisk":380,"seriousNumAffected":81,"seriousNumAtRisk":380,"otherNumAffected":316,"otherNumAtRisk":380},{"id":"EG001","title":"SB8 (A Proposed Bevacizumab Biosimilar)","description":"SB8 + Carboplatin/Paclitaxel\n\nSB8: SB8 15 mg/kg IV every 3 weeks on Day 1\n\nCarboplatin: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles\n\nPaclitaxel: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles","deathsNumAffected":166,"deathsNumAtRisk":378,"seriousNumAffected":75,"seriousNumAtRisk":378,"otherNumAffected":323,"otherNumAtRisk":378}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":380},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":378}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Cardiovascular insufficiency","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Right ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Optic atrophy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Inguinal hernia strangulated","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Small intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Gastric hypomotility","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Large intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Pancreatitis chronic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":380},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":378}]},{"term":"Infusion site extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Portal vein thrombosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":378}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Pyelonephritis chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Procedural pneumothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Suture rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Tumour lysis syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Carotid artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Haemorrhagic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Intercostal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Brachial plexopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Cystitis glandularis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":380},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":378}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":380},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":378}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":380},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":378}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Shock haemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":378}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":378}]},{"term":"Internal haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":380},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":378}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]},{"term":"Essential hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":380},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":378}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":107,"numAffected":87,"numAtRisk":380},{"groupId":"EG001","numEvents":102,"numAffected":87,"numAtRisk":378}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":119,"numAffected":69,"numAtRisk":380},{"groupId":"EG001","numEvents":122,"numAffected":74,"numAtRisk":378}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":45,"numAtRisk":380},{"groupId":"EG001","numEvents":96,"numAffected":57,"numAtRisk":378}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":23,"numAtRisk":380},{"groupId":"EG001","numEvents":59,"numAffected":39,"numAtRisk":378}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":224,"numAffected":79,"numAtRisk":380},{"groupId":"EG001","numEvents":177,"numAffected":74,"numAtRisk":378}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":24,"numAtRisk":380},{"groupId":"EG001","numEvents":38,"numAffected":29,"numAtRisk":378}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":380},{"groupId":"EG001","numEvents":32,"numAffected":24,"numAtRisk":378}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":380},{"groupId":"EG001","numEvents":24,"numAffected":20,"numAtRisk":378}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":43,"numAtRisk":380},{"groupId":"EG001","numEvents":58,"numAffected":49,"numAtRisk":378}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":46,"numAtRisk":380},{"groupId":"EG001","numEvents":56,"numAffected":46,"numAtRisk":378}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":28,"numAtRisk":380},{"groupId":"EG001","numEvents":37,"numAffected":37,"numAtRisk":378}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":24,"numAtRisk":380},{"groupId":"EG001","numEvents":48,"numAffected":32,"numAtRisk":378}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":30,"numAtRisk":380},{"groupId":"EG001","numEvents":47,"numAffected":29,"numAtRisk":378}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":18,"numAtRisk":380},{"groupId":"EG001","numEvents":50,"numAffected":28,"numAtRisk":378}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":27,"numAtRisk":380},{"groupId":"EG001","numEvents":36,"numAffected":26,"numAtRisk":378}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":34,"numAtRisk":380},{"groupId":"EG001","numEvents":39,"numAffected":36,"numAtRisk":378}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":92,"numAffected":46,"numAtRisk":380},{"groupId":"EG001","numEvents":117,"numAffected":46,"numAtRisk":378}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":35,"numAtRisk":380},{"groupId":"EG001","numEvents":37,"numAffected":24,"numAtRisk":378}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":16,"numAtRisk":380},{"groupId":"EG001","numEvents":55,"numAffected":19,"numAtRisk":378}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":54,"numAtRisk":380},{"groupId":"EG001","numEvents":39,"numAffected":38,"numAtRisk":378}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":32,"numAtRisk":380},{"groupId":"EG001","numEvents":33,"numAffected":32,"numAtRisk":378}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":27,"numAtRisk":380},{"groupId":"EG001","numEvents":29,"numAffected":26,"numAtRisk":378}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":35,"numAtRisk":380},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":378}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":24,"numAtRisk":380},{"groupId":"EG001","numEvents":25,"numAffected":17,"numAtRisk":378}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":380},{"groupId":"EG001","numEvents":26,"numAffected":24,"numAtRisk":378}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":380},{"groupId":"EG001","numEvents":25,"numAffected":23,"numAtRisk":378}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":30,"numAtRisk":380},{"groupId":"EG001","numEvents":21,"numAffected":21,"numAtRisk":378}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":380},{"groupId":"EG001","numEvents":28,"numAffected":20,"numAtRisk":378}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":184,"numAffected":183,"numAtRisk":380},{"groupId":"EG001","numEvents":185,"numAffected":184,"numAtRisk":378}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":35,"numAtRisk":380},{"groupId":"EG001","numEvents":60,"numAffected":46,"numAtRisk":378}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Director of Clinical Trials","organization":"Samsung Bioepis Co., Ltd","email":"sbregistry@samsung.com","phone":"031-8061-1096"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-08-18","uploadDate":"2022-07-01T01:31","filename":"Prot_000.pdf","size":3277303},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-04-18","uploadDate":"2022-07-01T01:33","filename":"SAP_001.pdf","size":3707205}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D008175","term":"Lung Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}